CompletedNCT03662425
Official study titleEffects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Behavioral Mechanisms
This study has finished and is no longer accepting participants.
In ShanghaiSchizophreniaMedication studyAges 18–55
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
CompletedNCT03714698
Official study titleEffects of Pilates-based Exercises on Functional Capacity and Mental Health in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In ZonguldakSchizophreniaPlacebo comparisonAges 35–40
- Countries
- Türkiye
- Sponsor
- Hacettepe University
CompletedNCT01523730
Official study titleEffects of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking and Cognitive Function in Smokers With and Without Schizophrenia
This study has finished and is no longer accepting participants.
In TorontoSchizophrenia, AddictionDevice studyAges 18–55
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT00770237
This study has finished and is no longer accepting participants.
In CatonsvilleSchizophrenia, AddictionBehavioural studyAges 18–64
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT01607840
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaInterventional studyAges 18–79
- Countries
- United States
- Sponsor
- Johns Hopkins University
CompletedNCT01934023
Official study titleEffects of Varenicline on Cortical Neuroplasticity and Working Memory in Patients With Schizophrenia and Healthy Controls
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaMedication studyAges 18–55
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT01850953
Official study titleEvaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaMedication studyAges 18–55
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
WithdrawnNCT00988728
Official study titleA Multicenter, Randomized, Parallel-Group, Double-blind, Fixed-Dose, 28-Day Trial to Assess the Efficacy and Safety of SCH 900435 Compared With Placebo, Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (GUEST - Glycine Uptake Inhibitor Efficacy and Safety Trial, Phase 2, Protocol No. P06079)
This study was withdrawn before enrollment.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT02970292
What is this study about?This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixSchizophreniaMedication studyAges 18–55
- Countries
- United States, Canada, Bulgaria, + 7 others
- Sponsor
- ACADIA Pharmaceuticals Inc.
TerminatedNCT00439634
What is this study about?Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.
This study ended early.
Multiple locations, including BridgewaterSchizophreniaMedication studyAges 18–65
- Countries
- United States, Canada
- Sponsor
- Sanofi
CompletedNCT02970305
What is this study about?This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixSchizophreniaMedication studyAges 18–55
- Countries
- United States, Canada, Bulgaria, + 7 others
- Sponsor
- ACADIA Pharmaceuticals Inc.
CompletedNCT00859872
About this title
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
Read the official source — NCT00859872What is this study about?This study evaluated the safety and effectiveness of risperidone oral solution for people with schizophrenia.
This study has finished and is no longer accepting participants.
In ChangshaSchizophreniaMedication studyAges 18–45
- Countries
- China
- Sponsor
- Central South University